Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Testim Gel

    - PMLiVE

    Endo faces industry-first FDA call to pull its opioid painkiller

    Misuse of Opana ER has been associated with a ‘serious’ HIV and hep C outbreaks

    - PMLiVE

    Endo buys Par for $8bn as M&A mania marches on

    Acquisitionwill make Endo the fifth largest generics company in the US

    - PMLiVE

    Valeant raises offer for Salix; rival Endo bows out

    Has increased bid to $173 per share in cash

    - PMLiVE

    Endo tries to ride out Valeant with $15.7bn bid for Salix

    Around $1.2bn more than rival bid

    - PMLiVE

    Endo to acquire Auxilium for $2.6bn

    Puts end to takeover deal for QLT

    - PMLiVE

    Endo’s $2.2bn bid for Auxilium Pharma could thwart QLT deal

    Auxilium in the $345m process of acquiring Canadian biotech company

    - PMLiVE

    Endo opts for Ogilvy PR

    Agency will provide PR support for Endo’s men’s health and pain management business

    - PMLiVE

    Endo builds pain management business

    Agrees $105m deal to acquire NuPathe

    - PMLiVE

    Auxilium’s Xiaflex cleared in US for erection disorder

    FDA approval to treat Peyronie's disease

    - PMLiVE

    Endo agrees $1.6bn deal to buy Paladin Labs

    Gives company access to Canada and emerging markets

    - PMLiVE

    Endo to collaborate with India-based CRO GVK Biosciences

    Will develop small molecule against undisclosed target in pain

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links